We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Thermo Fisher Scientific (TMO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Thermo Fisher Scientific is a member of our Medical group, which includes 845 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TMO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.56% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that TMO has returned about 22.65% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.89% on a year-to-date basis. As we can see, Thermo Fisher Scientific is performing better than its sector in the calendar year.
To break things down more, TMO belongs to the Medical - Instruments industry, a group that includes 94 individual companies and currently sits at #77 in the Zacks Industry Rank. Stocks in this group have gained about 11.48% so far this year, so TMO is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TMO as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Thermo Fisher Scientific (TMO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Thermo Fisher Scientific is a member of our Medical group, which includes 845 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TMO is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TMO's full-year earnings has moved 0.56% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that TMO has returned about 22.65% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.89% on a year-to-date basis. As we can see, Thermo Fisher Scientific is performing better than its sector in the calendar year.
To break things down more, TMO belongs to the Medical - Instruments industry, a group that includes 94 individual companies and currently sits at #77 in the Zacks Industry Rank. Stocks in this group have gained about 11.48% so far this year, so TMO is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TMO as it looks to continue its solid performance.